Proteomic Aging Clock (Organ-Specific)

The organ-specific proteomic aging clock was published in Nature Aging in November 2025 by Wang et al. It was trained in the UK Biobank on N=30,536 participants (7:3 training/testing split of a final dataset of N=43,616, ages 37-70, 54% women) using the Olink Explore 3072 assay that measures 2,916 unique proteins across cardiometabolic, inflammation, neurology, and oncology panels [1]. It was externally validated in the China Kadoorie Biobank (N=3,977, ages 30-78) with 11-16 year follow-up and in the US Nurses' Health Study (N=800, ages 43-69) with 30 year follow-up [1].

The key idea is organ specificity. The authors used 418 organ-enriched proteins to build separate age scores for brain, heart, liver, kidney, lung, immune system, muscle, and other organs, plus a whole-body 'conventional' clock. Older organ-specific age relative to chronological age predicts disease in that organ. In UK Biobank follow-up of up to 13 years, elevated brain-clock age predicted dementia, elevated heart-clock age predicted incident coronary disease and heart failure, and elevated whole-body age predicted all-cause mortality across all three cohorts [1].

Measurement uses a standard blood draw processed on the Olink Explore 3072 platform, then organ-enriched protein subsets scored through the published model. The assay is not yet direct-to-consumer, but SomaLogic's alternative aptamer-based platform is used in similar research pipelines [2]. Cost for the Olink assay ranges from several hundred to over 1,000 USD in a research context; not routinely covered by insurance.

Compared to first-generation epigenetic clocks like Horvath or Hannum, proteomic clocks have three advantages in these data: they use directly functional molecules rather than DNA methylation surrogates, they can be organ-resolved, and the same blood sample yields both a whole-body score and organ-specific scores. The UK Biobank paper reports that organ-specific proteomic age accelerations predicted 18-25 different age-related diseases with hazard ratios ranging from around 1.1 to 1.8 per standard-deviation increase in age acceleration [1].

No intervention has been shown in a controlled human trial to lower the organ-specific proteomic clock. Interventions that reduce inflammation, improve metabolic health, or reduce cardiovascular risk plausibly move the corresponding organ score, but this is inference from the underlying protein biology rather than demonstrated in a trial. Because the assay is proteomic rather than DNA-based, it should respond to intervention faster than DNA methylation clocks, but this hypothesis has not been tested.

Caveats: the training cohort was UK Biobank, which is majority white European, so calibration in more diverse populations depends on the external validation, which was done in Chinese and US cohorts but remains limited outside these. Olink and SomaLogic assays are not interchangeable, so a score from one platform cannot be directly compared to the other. The clock is a research tool as of mid-2026, not a clinical test.

The plain takeaway: this is the best-validated whole-body and organ-specific blood-protein age score published to date, with 48,000+ participants across UK, China, and US and up to 30 years of follow-up. It predicts disease and mortality well but no drug or supplement has been shown to lower it in a controlled human trial.